Companies › Il-Yang Pharm.
3 active drug programs in 5 registered trials: 3 Phase 3, 1 Phase 2, 1 Phase 1; Gastroenterology, Neurology, Oncology, Other; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Radotinib Bcr/Abl fusion protein inhibitor | ABL1, BCR | Phase 3 | Chronic Myeloid Leukemia, Chronic Phase; Parkinson Disease | Apr 2027 |
| Ilaprazole Potassium-transporting ATPase inhibitor | ATP4A, ATP4B | Phase 3 | Peptic Ulcer | Aug 2027 |
| IY-828026 | – | Phase 1 | Healhty | Mar 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07433556 | IY-828026 | Phase 1 | Healhty | Other | Mar 2027 |
| NCT04691661 | Radotinib | Phase 2 | Parkinson Disease | Neurology | Apr 2027 |
| NCT03459534 | Radotinib | Phase 3 | Chronic Myeloid Leukemia, Chronic Phase | Oncology | Jun 2027 |
| NCT06284876 | Ilaprazole | Phase 3 | Peptic Ulcer | Gastroenterology | Aug 2027 |
| NCT03722420 | Radotinib | Phase 3 | Chronic Myeloid Leukemia, Chronic Phase | Oncology | Dec 2027 |
Onconic Therapeutics InventisBio Guangzhou Lupeng Pharmaceutical Company SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany SK Life Science
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.